Halozyme Therapeutics Statistics

Total Valuation

Halozyme Therapeutics has a market cap or net worth of GBP 5.71 billion. The enterprise value is 6.42 billion.

Market Cap	5.71B
Enterprise Value	6.42B

Important Dates

The next estimated earnings date is Thursday, February 20, 2025.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-4.66%
Shares Change (QoQ)	+0.71%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	125.92M

Valuation Ratios

The trailing PE ratio is 19.50.

PE Ratio	19.50
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.06, with an EV/FCF ratio of 21.90.

EV / Earnings	21.91
EV / Sales	8.34
EV / EBITDA	14.06
EV / EBIT	16.57
EV / FCF	21.90

Financial Position

The company has a current ratio of 10.36, with a Debt / Equity ratio of 3.39.

Current Ratio	10.36
Quick Ratio	8.75
Debt / Equity	3.39
Debt / EBITDA	2.73
Debt / FCF	3.91
Interest Coverage	25.41

Financial Efficiency

Return on equity (ROE) is 111.83% and return on invested capital (ROIC) is 15.83%.

Return on Equity (ROE)	111.83%
Return on Assets (ROA)	14.87%
Return on Capital (ROIC)	15.83%
Revenue Per Employee	1.89M
Profits Per Employee	785,039
Employee Count	373
Asset Turnover	0.47
Inventory Turnover	1.92

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +61.54% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+61.54%
50-Day Moving Average	50.49
200-Day Moving Average	51.25
Relative Strength Index (RSI)	67.75
Average Volume (20 Days)	1,765

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.61

Income Statement

In the last 12 months, Halozyme Therapeutics had revenue of GBP 706.82 million and earned 292.82 million in profits. Earnings per share was 2.26.

Revenue	706.82M
Gross Profit	520.59M
Operating Income	355.90M
Pretax Income	358.20M
Net Income	292.82M
EBITDA	412.59M
EBIT	355.90M
Earnings Per Share (EPS)	2.26

Full Income Statement

Balance Sheet

The company has 497.13 million in cash and 1.15 billion in debt, giving a net cash position of -648.06 million.

Cash & Cash Equivalents	497.13M
Total Debt	1.15B
Net Cash	-648.06M
Net Cash Per Share	n/a
Equity (Book Value)	337.76M
Book Value Per Share	2.66
Working Capital	759.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 300.64 million and capital expenditures -7.64 million, giving a free cash flow of 293.00 million.

Operating Cash Flow	300.64M
Capital Expenditures	-7.64M
Free Cash Flow	293.00M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 73.65%, with operating and profit margins of 50.35% and 41.43%.

Gross Margin	73.65%
Operating Margin	50.35%
Pretax Margin	50.68%
Profit Margin	41.43%
EBITDA Margin	58.37%
EBIT Margin	50.35%
FCF Margin	41.45%

Dividends & Yields

Halozyme Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.66%
Shareholder Yield	4.66%
Earnings Yield	5.13%
FCF Yield	5.13%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Halozyme Therapeutics has an Altman Z-Score of 4.08.

Altman Z-Score	4.08
Piotroski F-Score	n/a